drugset / Trial / NCT00377104

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00377104

Phase 1 Terminated 24 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of flavopiridol in treating patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2006-09
Primary completion
2012-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule 30 mg/m2 Intravenous